Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RN3161 Monotherapy and Combination with Tirzepatide in Overweight and Obesity
NCT07245771Phase 2Recruiting
- Sponsor
- Ikaria
- Start
- Nov 2025
- Primary completion
- Feb 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
A Phase 2 trial of RN3161 in obesity, Overweight, sponsored by Ikaria. Started Nov 2025; status: recruiting.
02
Drugs
RN3161
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07245771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07245771.